Docoh
Loading...

TLIS Talis Biomedical

News

From Benzinga Pro
80 Biggest Movers From Yesterday
17 Nov 21
News, Penny Stocks, Small Cap, Pre-Market Outlook, Markets, Movers, Trading Ideas
Gainers BIMI International Medical Inc. (NASDAQ: BIMI) shares surged 55% to close at $1.00 on Tuesday as the company reported a narrower Q3 loss.
The Daily Biotech Pulse: Kezar Jumps On Data, Biogen R&D Chief To Retire, Molecular Partners Wilts On COVID Trial Disappointment
16 Nov 21
Biotech, Earnings, News, Penny Stocks, Offerings, Small Cap, General
Here's a roundup of top developments in the biotech space over the last 24 hours:
Talis Biomedical Q3 EPS $(1.49) Misses $(1.40) Estimate, Sales $218.00K Miss $1.46M Estimate
15 Nov 21
Earnings, News
Talis Biomedical (NASDAQ:TLIS) reported quarterly losses of $(1.49) per share which missed the analyst consensus estimate of $(1.40) by 6.43 percent. The company reported quarterly sales of $218.00 thousand which missed
Earnings Scheduled For November 15, 2021
15 Nov 21
Earnings, News, Pre-Market Outlook, Markets
Companies Reporting Before The Bell • Sohu.com (NASDAQ:SOHU) is estimated to report earnings for its third quarter.
64 Biggest Movers From Yesterday
9 Nov 21
News, Penny Stocks, Small Cap, Pre-Market Outlook, Markets, Movers, Trading Ideas
Gainers Pioneer Power Solutions, Inc. (NASDAQ: PPSI) shares jumped 219% to close at $10.40 on Monday after the company announced the launch of its E-Boost portfolio of mobile Electric Vehicle charging solutions for a full range of applications.
Why Are Talis Shares Trading Higher Today?
8 Nov 21
Long Ideas, News, Health Care, FDA, Movers, Trading Ideas, General
Talis Biomedical Granted FDA Emergency Use Authorization For COVID-19 Molecular Point-of-Care Test To Detect SARS-CoV-2
8 Nov 21
News, FDA
Authorized for use in a variety of healthcare and congregate settings, Talis One™ enables lab-quality results without the wait to detect or rule out COVID-19 in less than 30 minutes Talis One’s robust dual
The Daily Biotech Pulse: NRx Stitches COVID-19 Drug Partnership, Protara Gets Nod For Starting Bladder Cancer Study, IGM Moves Beyond Oncology
12 Oct 21
Biotech, Earnings, News, Penny Stocks, Offerings, Small Cap, FDA
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 11)
The Daily Biotech Pulse: Moderna Invests In Africa, Amgen Announces Neuroscience R&D Collaboration, Decision Day For Chemocentryx, Biophytis To Restate Results
7 Oct 21
Biotech, News, Penny Stocks, Offerings, Small Cap, FDA
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 6)
The Daily Biotech Pulse: J&J Files For Booster Dose Authorization, Gemini Restructures, Strata Skin CFO Departs, Kaleido Reports Positive Readout
5 Oct 21
Biotech, News, Penny Stocks, Offerings, Small Cap, FDA
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 4)
The Daily Biotech Pulse: Eisai, Biogen Pursue Approval Of Second Alzheimer's Treatment; Sanofi Changes mRNA Strategy; GSK Subsidiary To Develop Long-Acting HIV Preventive
28 Sep 21
Biotech, News, Penny Stocks, Small Cap, FDA
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 27)
12 Health Care Stocks Moving In Monday's Intraday Session
27 Sep 21
Intraday Update, Markets, Movers
Benzinga's Top Ratings Upgrades, Downgrades For September 27, 2021
27 Sep 21
Upgrades, Downgrades, Initiation, Intraday Update, Analyst Ratings
JP Morgan Downgrades Talis Biomedical to Underweight, Lowers Price Target to $7
27 Sep 21
News, Downgrades, Price Target, Analyst Ratings
JP Morgan analyst Tycho Peterson downgrades Talis Biomedical (NASDAQ:TLIS) from Neutral to Underweight and lowers the price target from $10 to $7.
The Daily Biotech Pulse: Aprea Jumps On ESMO Presentation, Verrica Sinks On Regulatory Setback, Aerie CEO Quits, J&J Touts Positive COVID-19 Booster Shot Data
21 Sep 21
Biotech, M&A, News, Penny Stocks, Offerings, Small Cap, FDA, Legal, General
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 20)

Press releases

From Benzinga Pro
The Law Offices of Frank R. Cruz Continues Investigation of Talis Biomedical Corporation (TLIS) on Behalf of Investors
3 Dec 21
Press Releases
LOS ANGELES, Dec. 3, 2021 /PRNewswire/ -- The Law Offices of Frank R. Cruz continues its investigation of Talis Biomedical Corporation ("Talis" or the "Company") (NASDAQ:TLIS) on behalf of investors
INVESTOR ALERT: Law Offices of Howard G. Smith Continues Its Investigation of Talis Biomedical Corporation (TLIS) on Behalf of Investors
3 Dec 21
Press Releases
BENSALEM, Pa., Dec. 3, 2021 /PRNewswire/ -- Law Offices of Howard G. Smith continues its investigation on behalf of Talis Biomedical Corporation ("Talis" or the "Company") (NASDAQ:TLIS) investors
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Continues Its Investigation of Talis Biomedical Corporation (TLIS) on Behalf of Investors
2 Dec 21
Press Releases
LOS ANGELES, Dec. 2, 2021 /PRNewswire/ -- Glancy Prongay & Murray LLP ("GPM"), a leading national shareholder rights law firm, continues its investigation on behalf of Talis Biomedical Corporation
Talis Biomedical Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2 Dec 21
Press Releases
MENLO PARK, Calif., Dec. 02, 2021 (GLOBE NEWSWIRE) -- Talis Biomedical Corporation (NASDAQ:TLIS), a company dedicated to advancing health equity and outcomes through the delivery of accurate infectious disease testing
Talis Biomedical Announces Appointment of Brian Blaser as President, Chief Executive Officer and Director
15 Nov 21
News, Management, Press Releases
Veteran executive previously led Abbott's global diagnostics organization Kim Popovits, interim chief executive officer, to resume role as Director on the Board of Talis MENLO PARK, Calif., Nov. 15, 2021 (GLOBE
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Continues Its Investigation of Talis Biomedical Corporation (TLIS) on Behalf of Investors
12 Nov 21
News, Legal, Press Releases
LOS ANGELES, Nov. 12, 2021 (GLOBE NEWSWIRE) -- Glancy Prongay & Murray LLP ("GPM"), a leading national shareholder rights law firm, continues its investigation on behalf of Talis Biomedical Corporation ("Talis" or
INVESTOR ALERT: Law Offices of Howard G. Smith Continues Its Investigation of Talis Biomedical Corporation (TLIS) on Behalf of Investors
11 Nov 21
News, Legal, Press Releases
BENSALEM, Pa., Nov. 11, 2021 (GLOBE NEWSWIRE) -- Law Offices of Howard G. Smith continues its investigation on behalf of Talis Biomedical Corporation ("Talis" or the "Company") (NASDAQ:TLIS) investors concerning the
Glancy Prongay & Murray LLP, a National Class Action Law Firm, Continues Investigation of Talis Biomedical Corporation (TLIS) on Behalf of Investors
14 Sep 21
Press Releases
Glancy Prongay & Murray L
INVESTOR ALERT: Law Offices of Howard G. Smith Continues Investigation of Talis Biomedical Corporation (TLIS) on Behalf of Investors
14 Sep 21
Press Releases
TALIS ALERT: Bragar Eagel & Squire, P.C. is Investigating Talis on Behalf of Talis Stockholders and Encourages Investors to Contact the Firm
13 Sep 21
Press Releases
Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Talis Biomedical Corporation ("Talis" or the "Company") (NASDAQ:TLIS) on behalf of Talis
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Talis Biomedical Corporation (TLIS) on Behalf of Investors
9 Sep 21
Press Releases
Glancy Prongay & Murray LL
The Law Offices of Frank R. Cruz Continues Investigation of Talis Biomedical Corporation (TLIS) on Behalf of Investors
9 Sep 21
Press Releases
The Law Offices of Frank R. Cruz continues its investigation of Talis Biomedical Corporation ("Talis" or the "Company") (NASDAQ:TLIS) on behalf of investors concerning the Company's possible violations of federal